PBA
EWTX icon

Paradigm Biocapital Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$11M – 32
2025
Q1 		$11M Buy
+500,000
New +$13.1M 0.5% 26

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Paradigm Biocapital Advisors's EWTX Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Edgewise Therapeutics (EWTX) stake by 13% in Q1 2026, buying an estimated $23.8M and bringing the position to 7,365,038 shares worth $232M. The position accounts for 4.74% of the portfolio, ranked #5.

Paradigm Biocapital Advisors first reported a position in EWTX in Q1 2024 and has held it in 9 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Paradigm Biocapital Advisors held 7,365,038 shares of Edgewise Therapeutics worth $232M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 823,828 Edgewise Therapeutics shares in Q1 2026, an estimated $23.8M.
  • Edgewise Therapeutics made up 4.74% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #5 holding.
  • Paradigm Biocapital Advisors first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.